Anavex Life Sciences Corp (AVXL)

[sokol]

Sorry, l was tired last night. I misunderstood your post.

I think Investors reply to your post is a good guess. I add the following:

In Parkinson disease dementia, postural instability and gait abnormalities are more common, motor decline is more rapid, and falls are more frequent than in Parkinson disease without dementia. https://www.merckmanuals.com/professional/neurologic-disorders/delirium-and-dementia/lewy-body-dementia-and-parkinson-disease-dementia

Our PDD trial ”...will focus on the effect of ANAVEX®2-73 on both the cognitive and motor impairment of Parkinson’s disease,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “We continue leveraging our precision medicine approach to drug development to provide intelligence beyond many traditional neurology trials to disease areas with high unmet needs.”’

”The brain changes caused by Parkinson’s disease begin in a region that plays a key role in movement. As Parkinson’s brain changes gradually spread, they often begin to affect mental functions, including memory and the ability to pay attention, make sound judgments and plan the steps needed to complete a task.[1]”
[1] Source: www.alz.org/dementia/parkinsons-disease-symptoms

https://www.anavex.com/anavex-life-sciences-receives-approval-to-initiate-phase-2-clinical-trial-of-anavex2-73-for-the-treatment-of-parkinsons-disease-dementia/

I suppose that if our drug is works in the PDD trial an improvement in noticeable/measurable movement and functions will be detectable in a shorter time frame. If improvement occurs with the 80% genetic group versus the 20% genetic group and/or the placebo group, it will be presumed that our drug is causing this meaningful result -- just my guess.